Furthermore, expression data from the Tumor Immune Dysfunction and Exclusion (TIDE) database, which includes expression data from bladder cancer patients treated with the ICI therapeutic anti-PD-L1, revealed that TMB was associated with the best response among nearly all other cancers. Here, CD274 is linked to urinary bladder cancer.